دكتوراهClosing soon

Associate researcher in Leukaemia Cell Quiescence and Treatment Resistance

EURAXESS hosting organisation · عدة بلدان أوروبية

Description of the workplace The research group is part of the Division of Molecular Medicine and Gene Therapy within the Faculty of Medicine, Lund University. In childhood B-cell acute lymphoblastic leukaemia (B-ALL), a subset of leukaemic cells survives chemotherapy by entering a dormant, quiescent state. These cells are thought to contribute to minimal residual disease and ultimately drive relapse. The group investigates the mechanisms underpinning this process using a human induced pluripotent stem cell (iPSC)-derived bone marrow organoid model engrafted with primary ALL cells, enabling the study of leukaemia-niche interactions that govern entry into quiescence. This platform is combined with an expressed barcode system that enables simultaneous tracking of lineage, cell state, and cel

At a glance

Where: Multiple European countries
Deadline: 2026-09-25
Funding: Funding described on programme page
Board: EURAXESS

Who can apply

Criteria stated by the funder on the official source.

Nationality

EURAXESS vacancies rarely print a nationality table. Confirm whether applicants from Tunisia can apply and whether a residence/work permit pathway exists on the employer page.

غير مذكور

Education

Research Field Medical sciences Education Level PhD or equivalent

غير مذكور

Funding and what it does not cover

Funding details were taken from the official programme page text. Confirm the current call before applying.